| scholarly article | Q13442814 |
| P50 | author | Josef S Smolen | Q66753681 |
| Daniel Aletaha | Q92095812 | ||
| P2860 | cites work | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score | Q24817087 |
| How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion | Q30688001 | ||
| Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group | Q33180020 | ||
| Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c | Q33213855 | ||
| Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states | Q33222832 | ||
| The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey | Q33235734 | ||
| Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components | Q33256077 | ||
| The importance of reporting disease activity states in rheumatoid arthritis clinical trials | Q33365105 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q33369384 | ||
| Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment | Q33436856 | ||
| Early rheumatoid arthritis: time to aim for remission? | Q33578559 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 | ||
| IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 | ||
| Osteoclasts are essential for TNF-alpha-mediated joint destruction | Q34826003 | ||
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials | Q35047250 | ||
| Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? | Q35554765 | ||
| Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results | Q35554892 | ||
| New therapies for treatment of rheumatoid arthritis | Q36849874 | ||
| Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility | Q36969898 | ||
| Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? | Q40901167 | ||
| Patients with rheumatoid arthritis in clinical care | Q41828498 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| A simplified disease activity index for rheumatoid arthritis for use in clinical practice | Q44321551 | ||
| Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). | Q44916043 | ||
| Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? | Q46707375 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. | Q51760068 | ||
| Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. | Q52225534 | ||
| A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. | Q52863944 | ||
| Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials | Q57169361 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q57169471 | ||
| Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes | Q57349649 | ||
| P433 | issue | 12 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 3702-3711 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints | |
| P478 | volume | 63 |
| Q48808090 | A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes |
| Q39325262 | A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control |
| Q53160625 | A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study. |
| Q35131783 | Advantages of a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and feet: does the RAMRIS of the hand alone underestimate disease activity and progression? |
| Q89099159 | Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study |
| Q36111299 | Assessment of synovitis to predict bone erosions in rheumatoid arthritis. |
| Q35827953 | Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in meth |
| Q42285413 | Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria |
| Q36045392 | Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients |
| Q36819270 | Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis |
| Q55191136 | Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? |
| Q38815347 | Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points |
| Q36164886 | Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study |
| Q38043946 | Damage assessment in ANCA-associated vasculitis. |
| Q91941010 | Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae |
| Q96953886 | Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q36414271 | Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition |
| Q45953331 | Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study. |
| Q36732733 | Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years |
| Q44241112 | Knee joint destruction driven by residual local symptoms after anti-tumor necrosis factor therapy in rheumatoid arthritis |
| Q31049240 | One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome |
| Q36709257 | Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis |
| Q48613748 | Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies |
| Q53307697 | Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. |
| Q37691184 | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
| Q92710530 | Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets |
| Q54800250 | Reply |
| Q87726283 | Rheumatoid arthritis |
| Q38357554 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges |
| Q44383497 | Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission |
| Q51543401 | Sonography Is Superior to Serum-Based Biomarkers for Measuring Disease Status in Experimental Rheumatoid Arthritis. |
| Q26784397 | Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis |
| Q42378691 | The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders |
| Q37715992 | The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy |
| Q43854069 | Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy |
| Q38476881 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force |
| Q46376552 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. |
| Q40949103 | VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis |
| Q39999268 | Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis |
| Q51104726 | Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. |
Search more.